Alpha-1 antitrypsin (A1AT) augmentation therapy has been shown to impact inflammatory markers such as C-reactive protein (CRP) in patients with Alpha-1 antitrypsin deficiency (AATD). The gene discussed is CRP; the disease is alpha 1-antitrypsin deficiency.